Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

October 1, 2014 Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “We wanted to study how …

New SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Announced

Fox Family Cancer Research Funding Trust Is Contributing to Support Team $8 million grant over three years will fund research focusing on novel immunotherapies for pancreatic cancer April 7, 2014 Stand Up To Cancer (SU2C),The Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announced the formation of a Dream …

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting

Study findings show enhanced therapeutic potential for vaccine when combined with cyclophosphamide and the checkpoint inhibitor anti-PD-1 April 7, 2014 Immunovaccine Inc., a clinical stage vaccine company, presented positive data from clinical and preclinical vaccine studies, including DPX-Survivac, the company’s lead therapeutic cancer vaccine, this weekend at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In a poster …